Our latest Eimear Darcy Guidelines in Practice from Medscape Medscape Primary Care #hack covering the 🔥hottest🔥 of topics: 🎯Use of incretin therapies for adults living with overweight & obesity PDF: medscape-uk.co/Hack-incretin #Hacks homepage: medscape-uk.co/Hacks I hope you find it helpful.

NEW PHASE 3 DATA: Topline results from our BROADWAY study—our largest Phase 3 clinical trial to date—evaluated obicetrapib, our investigational CETP inhibitor, in patients with ASCVD and/or HeFH who required additional lowering of their LDL-C levels. bit.ly/4gsIDm1

Mandatory training has lost its way. Once a tool for learning critical skills, it's now a growing list of endless requirements. If everything is mandatory, is anything truly essential? 🧵

Inclisiran gets yet more support from the NHS in England 🇬🇧 england.nhs.uk/publication/cv…

🚨 We have just published our commentary on the KETO CTA study! 🔥 Abstract as follows: “A recent study by Soto Mota et al. Nick Norwitz MD PhD Dave Feldman Adrian Soto-Mota has generated widespread attention for its claim that apolipoprotein B (ApoB) does not contribute to

🚨 When ‘high LDL causes heart disease’ becomes controversial, you know science is in trouble. The evidence showing that lifelong LDL exposure causes heart disease is arguably the strongest evidence base we have in all of medicine.

If anyone believes they can keep a lid on the use of GLP-1 analogue medicines for weight loss in the #NHS? They just need to see the signs all around People are choosing to avoid the “standard” means The #NHS would be better off trying to ensure safety measures are in place

New study result 🚨 Tirzepatide vs semaglutide SURMOUNT 5 RCT 📉Total body weight loss: −20.2% with tirzepatide −13.7% with semaglutide 🤢Discontinuations due to gastrointestinal events: tirzepatide 2.7%, semaglutide 5.6% 🤮vomiting tirzepatide 15.0% vs semaglutide 21.3%

Whilst we wait for the results of the inclisiran CVOTs this analysis led by Benoit Arsenault using instrument variables to mimic hepatic and circulating pcsk9 suggests it’s all proportional to atherogenic lipid change #hope track.smtpsendmail.com/9032119/c?p=z3…

"The NHS England interim guidance re 'Weight loss drugs' will leave primary care clinicians in the lurch. Because only a fraction of the population will be eligible, it will fall on clinicians to explain this “rationing.”" Via The BMJ cc Giles Yeo bmj.com/content/389/bm…

🚨 What’s the best diet for long-term health? There’s no single “best” diet —> but there are evidence-based principles that promote optimal health. 👍🏼 This post focuses on cardiovascular health - the leading cause of death globally: 🫀🧵

#CONFIDENCE built-in randomized withdrawal phase (after 180d of therapy) Reassuringly, early effects of combination therapy on: hemodynamics (BP lowering) electrolytes (K+ increase) kidney function (eGFR “dip”) all rapidly & fully reversible after drug cessation in just 30d!

⚠️In #T2D STATIN DELAY = CV RISK 💔 In 7,239 adults w/ diabetes (JAHA 2025): 🕒 1 in 5 delayed statins after initial offer 📈 LDL-C 126 vs 99 mg/dL (while off statin) 💔 CV event rate 10y: 8.5% (delay) vs 6.4% 💥 HR 1.49 for MI/stroke 🧪 LDL exposure mediated risk (HR 1.62)

🧬 ApoB Conformation and LDL Atherogenicity 👉This paper delves into how specific conformational changes in apolipoprotein B-100 impact LDL particle behavior — particularly its binding affinity to arterial wall proteoglycans. These structural transitions increase LDL retention

Why Do Patients Discontinue GLP-1 Medications for Obesity? Adherence Challenges ❌ 50% stop treatment within 6 months Top Reasons for Stopping 🤢 Side effects (mainly GI): 36% 🚗 Logistics (travel, time): 24% 💰 Cost & affordability: 23% dom-pubs.onlinelibrary.wiley.com/doi/full/10.11…

ALCHEMIST & ACHIEVE in The Lancet this week Spironolactone does not reduce cardiovascular morbidity / mortality in hemodialysis patients Huge congrats to Mike Walsh, Patrick Rossignol & all involved thelancet.com/journals/lance… thelancet.com/journals/lance…

Fantastic result for obicetrapib which reduced CV events at 12 months in a phase3a trial we have another tool in our war against CV disease coming 🤞🏻 ⭐️ Well done Steve Nicholls John Kastelein Prof Kausik Ray FMedSci ⭐️ Let’s see what the Prevail trial shows jacc.org/doi/10.1016/j.…

New updated NICE Heart Failure Guidelines. 🔘 HFrEF - offer RAASi + BB + MRA + SGLT2i 🔘 HFmrEF - SGLT2i + consider: RAASi + BB + MRA 🔘 HFpEF - SGLT2i + consider: MRA nice.org.uk/guidance/ng106

New The Lancet Meta-Analysis by #NelsonWang Brigham and Women's Hospital HF Fellow What is the expected BP lowering with various antihypertensive regimens? Robust model derived from n=104,176 pts across 484 RCTs Terrific user-friendly tool: bpmodel.org thelancet.com/journals/lance…

🔥 New in Nature Medicine How do you communicate lifetime benefits expected with HFpEF therapies? New data from 3 RCTs (#DELIVER #FINEARTS #PARAGON) estimate up to *5 years* of event-free survival w combination Rx #GDMT for HFpEF has finally arrived! 🔗nature.com/articles/s4159…